MX2008001818A - Uso de un fragmento de endoplasmina y derivados del mismo como un biomarcador para adenoma y/o carcinoma colorrectal, metodo para deteccion y sistema de prueba. - Google Patents

Uso de un fragmento de endoplasmina y derivados del mismo como un biomarcador para adenoma y/o carcinoma colorrectal, metodo para deteccion y sistema de prueba.

Info

Publication number
MX2008001818A
MX2008001818A MX2008001818A MX2008001818A MX2008001818A MX 2008001818 A MX2008001818 A MX 2008001818A MX 2008001818 A MX2008001818 A MX 2008001818A MX 2008001818 A MX2008001818 A MX 2008001818A MX 2008001818 A MX2008001818 A MX 2008001818A
Authority
MX
Mexico
Prior art keywords
colorectal
carcinoma
colorectal adenoma
directed
adenoma
Prior art date
Application number
MX2008001818A
Other languages
English (en)
Inventor
Hartmut Juhl
Kerstin David
Anne-Kristin Fentz
Original Assignee
Indivumed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivumed Gmbh filed Critical Indivumed Gmbh
Publication of MX2008001818A publication Critical patent/MX2008001818A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

La presente invencion esta dirigida a un metodo para detectar adenoma colorrectal y/o carcinoma colorrectal que comprende los pasos: a) proporcionar un material de muestra aislado que se ha tomado de un individuo, b) determinal el nivel de un fragmento de endoplasmina o un derivado del mismo en el material demuestra silado, c) comparar el nivel determinado del fragmento deendoplasmina o un derivado del mismo con uno o mas valores de referencia. La invencion esta dirigida ademas a un metodo para discriminar entre adenoma colorrectal y carcinoma colorrectal asi como un metodo para supervisar el desarrollo y/o curso de adenoma colorrectal y/o carcinoma colorrectal y/o el tratamiento de adenoma colorrectal y/o carcinoma colorrectal. Ademas, la invencion esta dirigida a un sistema de prueba y una disposicion para uso en estos metodos. Ademas la invencion esta dirigida al uso de un fragmento de endoplasmina como un biomarcador para una deteccion de adenoma colorrectal y/o carcinoma colorrectal en un individuo. Ademas, la invencion esta dirigida a un metodo para determinar la efectividad de un compuesto en el tratamiento de adenoma colorrectal y/o carcinoma colorrectal.
MX2008001818A 2005-08-19 2005-08-19 Uso de un fragmento de endoplasmina y derivados del mismo como un biomarcador para adenoma y/o carcinoma colorrectal, metodo para deteccion y sistema de prueba. MX2008001818A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/009005 WO2007019875A1 (en) 2005-08-19 2005-08-19 Use of an endoplasmin fragment and derivatives thereof as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system

Publications (1)

Publication Number Publication Date
MX2008001818A true MX2008001818A (es) 2008-04-09

Family

ID=36087694

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001818A MX2008001818A (es) 2005-08-19 2005-08-19 Uso de un fragmento de endoplasmina y derivados del mismo como un biomarcador para adenoma y/o carcinoma colorrectal, metodo para deteccion y sistema de prueba.

Country Status (13)

Country Link
US (1) US8580489B2 (es)
EP (1) EP1917530B1 (es)
JP (1) JP4832519B2 (es)
KR (1) KR101314959B1 (es)
AT (1) ATE499612T1 (es)
AU (1) AU2005335652A1 (es)
BR (1) BRPI0520483A2 (es)
CA (1) CA2617214C (es)
DE (1) DE602005026587D1 (es)
IL (1) IL189185A0 (es)
MX (1) MX2008001818A (es)
NO (1) NO20080510L (es)
WO (1) WO2007019875A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101669031A (zh) * 2007-02-27 2010-03-10 森托科隆股份公司 使用与细胞外标记物结合的试剂组多重检测肿瘤细胞
CN109584961A (zh) * 2018-12-03 2019-04-05 元码基因科技（北京）股份有限公司 基于二代测序技术检测血液微卫星不稳定的方法
CN110244047B (zh) * 2019-06-10 2023-11-03 广州市妇女儿童医疗中心 肺癌血清诊断标志物及其应用、肺癌相关可溶性蛋白的分离鉴定方法
KR20240068432A (ko) * 2022-11-10 2024-05-17 을지대학교 산학협력단 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019967A1 (de) * 2000-04-20 2001-10-25 Fenning Biomed Gmbh Dr Antikörper gegen natives gp96, deren Herstellung und Verwendung
ATE370414T1 (de) 2002-12-20 2007-09-15 Hoffmann La Roche Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
BRPI0520483A2 (pt) 2009-11-10
CA2617214C (en) 2013-02-12
KR101314959B1 (ko) 2013-10-11
ATE499612T1 (de) 2011-03-15
IL189185A0 (en) 2008-06-05
US20100273668A1 (en) 2010-10-28
JP2009505080A (ja) 2009-02-05
CA2617214A1 (en) 2007-02-22
DE602005026587D1 (de) 2011-04-07
WO2007019875A1 (en) 2007-02-22
KR20080036652A (ko) 2008-04-28
EP1917530A1 (en) 2008-05-07
NO20080510L (no) 2008-05-19
AU2005335652A1 (en) 2007-02-22
EP1917530B1 (en) 2011-02-23
JP4832519B2 (ja) 2011-12-07
US8580489B2 (en) 2013-11-12

Similar Documents

Publication Publication Date Title
ZA200701188B (en) Use of C3a and derivatives thereof as a biomarker for colorectal ademona and/or carcinoma; diagnosis method and test system using the same
WO2013093635A3 (en) Plasma micrornas for the detection of early colorectal cancer
WO2008134526A3 (en) Glycoprotein profiling of bladder cancer
WO2005041893A3 (en) Detection of acute myocardial infarction biomarkers
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
IN2013CN01129A (es)
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
EP3156925A3 (en) Copd biomarker signatures
WO2009073505A3 (en) Methods for processing tandem mass spectral data for protein sequence analysis
WO2009113044A3 (en) Method for a highly sensitive detection and quantification of biomolecules using secondary ion mass spectrometry (sims)
WO2010009074A3 (en) Method for predicting and detecting tumor metastasis
WO2004057336A3 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
IL189185A0 (en) Use of an endoplasmin fragment and derivatives thereof as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system
GB201222576D0 (en) Method for diagnosing lung cancer
WO2003076896A3 (en) Use of biomarkers to detect breast cancer
WO2014044791A3 (en) Methods and kits for predicting the sensitivity of a subject to chemotherapy
WO2005050203A3 (en) The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis
WO2012045324A8 (en) Method for detecting a parkinson's disease and test system
WO2007062142A3 (en) Method for identifying biomarkers associated with cancer
WO2020210326A3 (en) Clinical prognostication test in uveal melanoma
MY162282A (en) Improved method for a highly sensitive detection and quantification of biomolecules using secondary ion mass spectrometry (sims) and related technologies
WO2017156154A9 (en) Compositions for characterizing development of esophageal adenocarcinoma in patients and methods of use thereof
BRPI0514314A (pt) método para detecção de e discriminação entre adenoma colorretal e/ou carcinoma colorretal, método para monitoramento de desenvolvimento e/ou curso e/ou de tratamento de adenoma colorretal e/ou carcinoma colorretal, uso de c3a ou derivado do mesmo, sistema de teste, conjunto compreendendo moléculas, método para determinar se um composto é efetivo no tratamento do adenoma colorretal e/ou carcinoma colorretal

Legal Events

Date Code Title Description
FG Grant or registration